Drug Profile
URG 301
Alternative Names: URG301Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Urigen Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Overactive bladder; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Overactive bladder in USA (Transurethral, Suppository)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in USA (Transurethral, Suppository)
- 24 Aug 2007 Phase-I clinical trials in Overactive bladder in USA (Transurethral)